Context Therapeutics Inc. — Q3 2021 Form 10-Q
Reporting period: Three and nine months ended September 30, 2021; filed December 2, 2021. Context is a clinical-stage biopharmaceutical company developing therapies for women’s cancers. Its lead candidate is ONA-XR; its pipeline also includes a CLDN6 bispecific antibody. The company reported no product revenue and operates as one segment.
Financial results and liquidity
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development | $0.74 million | $0.47 million | $2.51 million | $1.05 million |
| General and administrative | $0.83 million | $0.18 million | $1.83 million | $0.76 million |
| Acquired in-process R&D | — | — | $3.09 million | — |
| Net income (loss) | $(1.44) million | $(0.88) million | $(7.37) million | $7.43 million |
| Cash used in operating activities | Not separately presented | $3.84 million | $0.86 million |
At September 30, cash and cash equivalents were $0.42 million, total current liabilities were $4.41 million, and accumulated deficit was $26.16 million. The filing does not provide a meaningful operating margin; the company had no revenue. Convertible promissory notes had been converted by February 2021, and the PPP loan was forgiven in July; no note payable remained at quarter-end.
Nine-month investing cash use was $0.25 million, and financing provided $4.17 million, primarily from Series A preferred stock proceeds, partly offset by IPO offering costs. Cash increased $0.08 million over the period. The $7.43 million prior-year nine-month net income was not indicative of operating profitability: it included a $9.80 million noncash gain from changes in fair value of convertible notes.
Material changes and notable items
- Q3 net loss widened by $0.57 million year over year as R&D and G&A spending increased. Management attributed higher R&D to ONA-XR Phase 2 trial work, CLDN6 preclinical research, and consulting; G&A rose with staffing, share-based awards, and public-company preparation.
- Nine-month operating expenses increased substantially, including $3.09 million of acquired in-process R&D related to the Integral Molecular CLDN6 agreement. The consideration included an upfront fee and Series A shares.
- In October 2021, the company completed an IPO of 5.75 million shares at $5.00 per share, generating $28.75 million gross and approximately $24.4 million net proceeds. Preferred stock converted into common stock at the IPO.
- On December 1, 2021, the company agreed to a private placement of 5.0 million shares plus warrants for 5.0 million shares, for approximately $31.3 million gross proceeds. At filing, closing was expected December 6, subject to customary conditions.
- Management said the IPO proceeds and expected private-placement proceeds, together with existing cash, were expected to fund operations into 2024. The filing also states that substantial additional financing will be needed to develop and commercialize candidates.
Outlook, risks, and contingencies
No formal revenue or earnings guidance was provided. Management expects continuing operating losses and rising R&D, G&A, and capital needs as it advances ONA-XR and CLDN6, scales manufacturing, and operates as a public company. Future funding needs depend on development results, trial scope and timing, manufacturing, staffing, regulatory work, and other factors; further financing may dilute shareholders or require unfavorable terms.
Key risks include clinical and regulatory uncertainty, reliance on third parties for trials and manufacturing, intellectual-property challenges, competition, and potential COVID-19-related trial delays, enrollment constraints, vendor disruption, and added costs. The Tyligand agreement includes process-development and manufacturing milestone payments and potential royalties; the Integral agreement includes up to $55.3 million in development and regulatory milestones, up to $130 million in sales milestones, and tiered royalties. The company reported no material legal proceedings.
Management disclosed material weaknesses in internal control over financial reporting, involving financial-statement review and segregation of accounting duties, and said remediation was underway through added accounting staff and outside consultants. It reported no material changes to the risk factors in its IPO prospectus.
Important facts for investors to verify
- Whether the December private placement closed on expected terms, and the resulting cash balance, share count, warrant dilution, and runway.
- Progress, enrollment, timing, and results for ONA-XR’s Phase 2 trial and development of the CLDN6 candidate.
- Actual cash burn and whether management’s runway estimate into 2024 remains achievable under development and public-company spending plans.
- Remediation and subsequent assessment of the disclosed internal-control material weaknesses.
- Potential milestone, royalty, and other obligations under the Tyligand and Integral agreements.